Dabur Pharma Ltd has acquired the entire oncology (anti-cancer) sales and distribution business from its partner Biosciences Company Ltd in Thailand for an undisclosed amount. The acquisition has been done through its wholly owned subsidiary in the country.

This acquisition greatly strengthens the Dabur's presence in the Thai oncology generics market, where it is already the market leader. It would allow the Dabur to significantly extend its reach and presence.

"Acquiring the sales and distribution channel is another important step in the oncology led growth strategy that we are actively pursuing," commented Dr Anand Burman, chairman, of the company. He further mentioned that the company would increasingly focus on its competencies in the oncology business to drive growth both in the generics and the NDDS market.

Ajay Vij, COO, of the company said "This acquisition is in line with the company strategy of expanding its oncology foothold in the various markets it operates in." The oncology market in Thailand is estimated to be growing at the rate of 25 per cent. Dabur, which entered the market in 1999, is currently growing at 29 per cent and has a market share of approximate 17 per cent amongst the generic companies.